title: CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis.
abstract: We studied dipeptidyl peptidase IV (DPP-IV, CD26) expression in different T helper cells and serum soluble DPP-IV/sCD26 levels in rheumatoid arthritis (RA) patients, correlated these with disease activity score (DAS), and examined how they were affected by different therapies, conventional or biological (anti-TNF, anti-CD20 and anti-IL6R or Ig-CTLA4). The percentage of CD4+CD45R0+CD26- cells was greatly reduced in patients (up to 50%) when compared with healthy subjects. Three other subsets of CD4 cells, including a CD26high Th1-associated population, changed variably with therapies. Data from these subsets (frequency and staining density) significantly correlated with DAS28 or DAS28 components but different in each group of patients undergoing the different therapies. Th17 and Th22 subsets were implicated in RA as independent CCR4+ and CCR4- populations each, with distinct CD26 expression, and were targeted with varying efficiency by each therapy. Serum DPP-IV activity rather than sCD26 levels was lower in RA patients compared to healthy donors. DPP-IV and sCD26 serum levels were found related to specific T cell subsets but not to disease activity. We conclude that, according to their CD26 expression, different cell subsets could serve to monitor RA course, and an uncharacterized T helper CD26- subset, not targeted by therapies, should be monitored for early diagnosis.
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: Oscar J
authors.initials: OJ
authors.lastname: Cordero
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: Rubén
authors.initials: R
authors.lastname: Varela-Calviño
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: Tania
authors.initials: T
authors.lastname: López-González
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Calviño-Sampedro
authors.affiliation: Service of Immunology, University Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: Juan E
authors.initials: JE
authors.lastname: Viñuela
authors.affiliation: Service of Rheumatology, University Hospital Complex of Vigo, Vigo, Spain; IRIDIS (Investigation in Rheumatology and Immuno-mediated Diseases) Group, Instituto de Investigación Biomédica. Xerencia de Xestión Integrada-SERGAS, Vigo, Spain.
authors.forename: Coral
authors.initials: C
authors.lastname: Mouriño
authors.affiliation: Service of Rheumatology, University Hospital Complex of Vigo, Vigo, Spain.
authors.forename: Íñigo
authors.initials: Í
authors.lastname: Hernández-Rodríguez
authors.affiliation: Service of Rheumatology, University Hospital Complex of Vigo, Vigo, Spain; IRIDIS (Investigation in Rheumatology and Immuno-mediated Diseases) Group, Instituto de Investigación Biomédica. Xerencia de Xestión Integrada-SERGAS, Vigo, Spain.
authors.forename: Marina
authors.initials: M
authors.lastname: Rodríguez-López
authors.affiliation: Service of Rheumatology, University Hospital Complex of Vigo, Vigo, Spain.
authors.forename: Bruno
authors.initials: B
authors.lastname: Aspe de la Iglesia
authors.forename: José María
authors.initials: JM
authors.lastname: Pego-Reigosa
authors.affiliation: Service of Rheumatology, University Hospital Complex of Vigo, Vigo, Spain; IRIDIS (Investigation in Rheumatology and Immuno-mediated Diseases) Group, Instituto de Investigación Biomédica. Xerencia de Xestión Integrada-SERGAS, Vigo, Spain.
authors.forename: José María
authors.initials: JM
authors.lastname: Pego
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D003710:Demography; D018819:Dipeptidyl Peptidase 4 / Q000097:blood* / Q000235:genetics* / Q000378:metabolism; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D017493:Leukocyte Common Antigens / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D016176:T-Lymphocyte Subsets / Q000166:cytology / Q000378:metabolism; D006377:T-Lymphocytes, Helper-Inducer / Q000166:cytology / Q000276:immunology / Q000378:metabolism*; D058504:Th17 Cells / Q000166:cytology / Q000276:immunology
chemical_list: D018501:Antirheumatic Agents; D017493:Leukocyte Common Antigens; C516769:PTPRC protein, human; D018819:Dipeptidyl Peptidase 4